Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of 3% Diquafosol versus 0.3% Hyaluronic Acid Eye Drops in Hemifacial Spasm Treated with Botulinum Toxin A
TCTR20251021007Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Oct 2025
- Countries
- 1
- Sponsor
- Akarawit Eiamsamarng
- Modality
- Small Molecules
- Drugs
- diquafosol
- Conditions
- hemifacial spasm (HFS)dry eye syndrome (DED)
01
Overview
Phase 2, randomised trial of diquafosol in hemifacial spasm (HFS) and dry eye syndrome (DED) (2 arms), sponsored by Akarawit Eiamsamarng. Planned start Oct 2025; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Sequence 1: Diquafosol → Hyaluronic Acid
Participants receive 3% diquafosol eye drops in the first period followed by 0.3% hyaluronic acid eye drops in the second period, on a background of botulinum toxin A for hemifacial spasm.
Sequence 2: Hyaluronic Acid → Diquafosol
Participants receive 0.3% hyaluronic acid eye drops in the first period followed by 3% diquafosol eye drops in the second period, on a background of botulinum toxin A for hemifacial spasm.
Beyond the preview
Go deeper on TCTR20251021007.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251021007.